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Primary (AL) amyloidosis of the gastrointestinal tract is relatively rare, and symptomatic amyloidosis of the stomach is even more
seldom. We present the case of a patient who was referred to upper endoscopy because of weight loss, nausea, and vomiting. Large
areas of intramucosal hemorrhages were seen, and biopsies resulted in profuse bleeding stopped with endoscopic clips.The biopsies
showed amyloid depositions and further workup revealed that the patient also had cardiac and neuropathic involvements. The
patient started treatment with dexamethasone, melphalan and bortezomib. After treatment was started the nausea and epigastric
discomfort improved, and a reduction in the biochemical markers troponin T, NT-proBNP, and M-component was observed.
Gastric amyloidosis is rarely seen at upper endoscopy in patients without a previously established diagnosis, but the unusual
endoscopic findings and bleeding tendency after biopsy should be kept in mind by gastroenterologists.
1. Introduction
Gastrointestinal involvement in amyloidosis is seen in pri-
mary (AL) amyloidosis, secondary (AA) amyloidosis, and
dialysis-related (𝛽2-microglobulin) amyloidosis.
Primary (AL) amyloidosis of the gastrointestinal tract
is relatively rare, and only 8% of patients were reported to
have amyloidosis in biopsies from the GI tract, whereas only
1% had symptomatic amyloidosis of the stomach in a series
of 769 patients [1]. Amyloidosis involving the gastrointesti-
nal tract may cause symptoms related to altered motility,
gastrointestinal bleeding, or malabsorption. In the stomach,
gastric amyloidosis may have an endoscopic appearance
mimicking gastric neoplasia [2, 3], hematomas, erosions and
ulcerations, or a nodular gastritis [4]. The diagnosis of gas-
trointestinal amyloidosis may be hard to suspect in patients
without previously diagnosed inflammatory or plasma cell
disease.
2. Case
A 74-year-old woman was referred to upper gastrointestinal
endoscopy due to weight loss of 10 kg in 6 months, epigastric
discomfort, nausea, and episodes of vomiting. She had a
previous history of a tachy-brady syndrome resulting in pace-
maker implantation two years before and receivedmetoprolol
treatment.
Upper endoscopy showed large areas of intramucosal
hemorrhage, mainly in the corpus and cardia of the stomach,
whereas in the duodenal bulb, there was a polypoid lesion
(Figure 1). A biopsy was taken from a small area with modest
signs of intramucosal hemorrhage resulted in a profuse bleed-
ing that was stopped with endoscopic clips. Biopsy collection
from the polypoid lesion in the duodenum was apparently
uncomplicated. In the evening, after the endoscopy, the
patient had one episode of red hematemesis, but endoscopy
the next day did not reveal the bleeding site, and Hb was
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Figure 1: Endoscopic appearance of the corpus and cardia of the stomachwith large areas of intramucosal hemorrhage (a) and of the duodenal
bulb with a polypoid lesion (b).
(a) (b)
(c) (d)
Figure 2: Biopsies from the gastric corpus stained with Congo red, with extracellular deposits between the gastric glands (a) and apple-
green birefringence seen under polarized light (b). Immunohistochemical examination of a bone marrow biopsy showed a normal density of
immunoglobulin kappa (𝜅) chain (c) and an increased density of immunoglobulin lambda (𝜆) chain positive cells (d).
13.8 g/dL. Histological examination of the biopsies from the
stomach showed amyloid deposits, and the lesion in the duo-
denal bulb was ectopic gastric mucosa with amyloid deposits
(Figure 2).
Subsequent diagnostic examinations revealed mono-
clonal component at serum electrophoresis quantified as
immunoglobulin G (IgG) 𝜆 6.4 g/L. Bone marrow biopsy
showed a slight increase in plasma cells positive for light
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chain 𝜆 as a sign of monoclonal plasma cell expansion
(Figure 2). These bone marrow changes did not fulfill cri-
teria for multiple myeloma and were considered compat-
ible with monoclonal gammopathy of unknown signifi-
cance (MGUS). Further workup demonstrated considerable
myocardial thickening by echocardiography with a reduced
short axis contraction compatible with amyloid deposition.
High troponin T (60 ng/L) and NT-proBNP (15000 ng/L)
values were found, indicating stage III cardiac involvement,
which has a dismal prognosis. Additionally, the patient
had neuropathic pain, neurographic signs of axonal, and
demyelinating sensorimotor polyneuropathy, also assumed
to be caused by amyloid deposition. The diagnosis was
hence AL amyloidosis with gastroduodenal, cardiac, and
neuropathic involvements.The patient started treatmentwith
dexamethasone, melphalan, and bortezomib which has been
shown to induce a very high rate of deep biochemical
response in multiple myeloma with improved survival [5].
Amyloidosis has previously been considered as a condition
not amenable to treatment, but it is important to know
that combinations of either melphalan or bortezomib with
dexamethasone can induce organ responses in about 30–50%
of patients with amyloidosis [6]. After treatment started, the
nausea and epigastric discomfort improved and a reduction
in biochemical markers such as troponin T, NT-proBNP, and
M-component was observed.
3. Discussion
Symptomatic gastric involvement is rare in patients with
AL amyloidosis. This patient had large intramucosal hemor-
rhages and a polypoid lesion in the duodenum, where biop-
sies at upper endoscopy resulted in bleeding, but revealed
amyloid deposits and led to the diagnosis of AL amyloidosis.
Large hemorrhages requiring blood transfusion after biopsies
from gastric amyloid lesions have been described by others
[4] andmay be related to small-vessel fragility due to amyloid
infiltration and impaired hemostasis caused by factor X
deficiency [7]. Bleeding diathesis has been observed in AL
amyloidosis also under other circumstances and may cause
purpura [8] and increase the risk of bleeding after liver biopsy
[9].
The diagnosis of gastric AL amyloidosis should be consid-
ered in patients with plasma-cell disease. Gastric amyloidosis
is rarely seen at upper endoscopy in patients without a
previously established diagnosis, and only few endoscopic
findings have been published, but the differential diagnosis
should be kept in mind by gastroenterologists.
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